Department of Neurological Surgery, University of California, San Francisco, CA, USA.
Adv Exp Med Biol. 2012;746:26-40. doi: 10.1007/978-1-4614-3146-6_3.
This chapter contains an overview of standard of care and experimental chemotherapy treatments for glioblastoma multiforme (GBM). We discuss the role of alkylating agents, focusing primarily on temozolomide (TMZ) which, in combination with radiation therapy, is part of the standard of care treatment for newly diagnosed GBM. TMZ has proven both well tolerated and effective in prolonging patient survival, but tumor recurrence remains the rule. We review the development and use of molecularly targeted agents, low molecular weight kinase inhibitors and monoclonal antibodies that interrupt the signaling pathways exploited by tumors to grow, migrate and avoid apoptosis.
本章概述了胶质母细胞瘤（GBM）的标准护理和实验性化疗治疗。我们讨论了烷化剂的作用，主要关注替莫唑胺（TMZ），TMZ 与放射治疗联合，是新诊断 GBM 的标准护理治疗的一部分。TMZ 已被证明具有良好的耐受性和有效性，可以延长患者的生存时间，但肿瘤复发仍然是常态。我们回顾了分子靶向药物、低分子量激酶抑制剂和单克隆抗体的开发和使用，这些药物可以阻断肿瘤用来生长、迁移和逃避细胞凋亡的信号通路。
